Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An update from Wai Chun Bio-Technology Ltd. ( (HK:0660) ) is now available.
Wai Chun Bio-Technology Limited has clarified that, although a majority shareholder holding about 51.3% of its issued shares had previously provided written approval for certain loan drawdowns, the board has now resolved to convene a general meeting to seek broader shareholder approval. This shift follows a delay in dispatching the required transaction circular within the original 15-business-day window stipulated by listing rules, prompting the company to include a notice of extraordinary general meeting in the forthcoming circular.
The company further announced an additional postponement to the dispatch of this circular, which will now be sent to shareholders on or before 25 April 2026 to allow more time to prepare and finalize the information it must contain. The delays and change of approval method underscore Wai Chun Bio-Technology’s need to align its loan-related transaction processes with Hong Kong listing requirements, with implications for the timing and transparency of decision-making for shareholders and other stakeholders.
More about Wai Chun Bio-Technology Ltd.
Wai Chun Bio-Technology Limited is a Cayman Islands-incorporated company listed on the Hong Kong Stock Exchange, operating under stock code 660. The company is involved in bio-technology-related businesses, though this announcement primarily focuses on its corporate financing and compliance arrangements rather than specific products or services.
Average Trading Volume: 144,142
Technical Sentiment Signal: Buy
Current Market Cap: HK$45.51M
See more insights into 0660 stock on TipRanks’ Stock Analysis page.